The NUB1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the NUB1 gene in the human Raji B lymphocyte cell line. This polyclonal knockout model, generated via CRISPR/Cas9-mediated gene disruption, provides a heterogeneous pool of edited cells for studying the functional consequences of NUB1 loss. The cells are offered as a ready-to-use population, allowing researchers to investigate the role of NUB1 in regulating the NEDD8 conjugation pathway and its associated cellular processes.
The Raji cell line is a widely used EBV-positive human Burkitt lymphoma-derived B lymphocyte line that grows in suspension. Originating from a pediatric patient, Raji cells are extensively employed in oncology and immunology research due to their robust B cell receptor signaling, capacity for antibody production, and relevance to humoral immune responses. This background makes them particularly suitable for dissecting signaling mechanisms in B-cell malignancies and immune regulation.
NUB1 encodes a negative regulator of the NEDD8 conjugation pathway, which modulates the activity of cullin-RING ubiquitin ligases (CRLs). The NUB1 protein selectively binds NEDD8 and NEDD8-modified conjugates, recruiting them to the 26S proteasome for degradation. This function directly impacts the ubiquitin-proteasome system and downstream pathways such as NF-??B signaling and apoptosis. NUB1 interacts with key molecular partners including NEDD8, ubiquitin, synphilin-1, ataxin-3, and 26S proteasome regulatory subunits. Upstream, NUB1 expression is induced by interferon gamma (IFN-??) and is responsive to proteasome stress. Through its action on CRLs, NUB1 influences the stability of critical substrates such as p27 and I??B??, thereby affecting cell cycle progression and inflammatory signaling.
In the context of Raji B lymphoma cells, disruption of NUB1 is anticipated to alter the balance of NEDD8 conjugation and deconjugation, leading to dysregulated cullin-RING ligase activity. This may result in altered turnover of downstream targets, impacting processes like NF-??B-mediated transcription and apoptosis sensitivity. Given the role of NUB1 in targeting synphilin-1 for degradation, this model also offers a valuable tool for exploring links between the NEDD8 pathway and neurodegenerative pathologies such as Parkinson??s disease. The EBV-positive nature of Raji cells further expands the model??s utility in studying viral latency and immune evasion in B-cell contexts.
These polyclonal knockout cells are suitable for a broad range of experimental applications, including mechanistic studies of the NEDD8 pathway in B-cell lymphoma, functional analysis of IFN-??-responsive genes, and drug sensitivity profiling with neddylation inhibitors like MLN4924. The cells support detailed biochemical assays such as immunoblotting to assess global NEDD8 conjugates and cullin neddylation, RT-qPCR for NUB1 and interferon-responsive gene expression, flow cytometry for cell cycle and apoptosis quantitation, proteasome activity measurements, and co-immunoprecipitation of NEDD8-modified protein complexes. For further assistance, please contact Ascent Research.
